ライフサイエンスコーパス: maintenance dose

1 ophils, sputum EoP numbers or the prednisone maintenance dose.

2 d (75 mg; n=20) or high (150 mg; n=20) daily maintenance dose.

3 ieved long-term euthyroidism off CBZ or on a maintenance dose.

4 at decreased iPTH by at least 30% became the maintenance dose.

5 the study drug or administration of the last maintenance dose.

6 kinetic parameters and calculate the optimum maintenance dose.

7 ly with both prasugrel and ticagrelor LD and maintenance dose.

8 ed less than 60 kg received a 5-mg prasugrel maintenance dose.

9 val were similar at both induction doses and maintenance doses.

10 ocaine self-administration across a range of maintenance doses.

11 nts were updosed weekly, followed by monthly maintenance dosing.

12 during dose escalation and after 6 months of maintenance dosing.

13 200 mg given every second week thereafter as maintenance dosing.

14 ntly high reactivity with clopidogrel 150-mg maintenance dosing.

15 primary PCI cohort) continued taking an oral maintenance dose (0.5 mg, 1.0 mg, or 2.5 mg per day), an

16 an intravenous loading dose (800 mg) plus 5 maintenance doses (200 mg every 12 hours) of gavestinel

17 phenobarbital (1.5 mg/kg daily for 2 weeks; maintenance dose 3.0 mg/kg daily; n = 47) or phenytoin (

18 n via a web-based service to oral phenytoin (maintenance dose 4 mg/kg per day if randomised before or

19 ts who lost response could be treated with a maintenance dose 5 mg/kg higher.

20 trastuzumab (50 mg/kg loading dose, 25 mg/kg maintenance dose, administered intraperitoneally twice a

21 g postmyocardial infarction, yet its optimal maintenance dose after percutaneous coronary interventio

22 cation had blood sampling in the morning pre-maintenance dose and again 2 h post-dose.

23 ed analyses, both Cox regression with median maintenance dose and landmark techniques showed that, in

24 on warfarin (n = 83) or fluindione (n = 35) maintenance dose and the influence of these factors on t

25 plications for the alteration in clopidogrel maintenance dose and use of glycoprotein IIb/IIIa inhibi

26 r p 1 (when reported) were 0.8 to 70 mug for maintenance doses and 60 to 23,695 mug for cumulative do

27 (when reported) ranged from 7 to 30 mug for maintenance doses and 60 to 420 mug for cumulative doses

28 irs, 13% involved bolus dosing, 49% involved maintenance dosing, and 38% did not include exposure to

29 erlying statistical interaction with aspirin maintenance dose as a possible explanation for the regio

30 ed patients with myocardial infarction, high-maintenance-dose aspirin was associated with similar rat

31 4 mg/kg intravenously, followed by a 2-mg/kg maintenance dose at weekly intervals.

32 re are no major metabolic differences on low maintenance doses between FK-506 and CsA.

33 nd 64% of the patients attained their CsA-ME maintenance dose by study week 4.

34 Compared with no iron, maintenance dosing did not associate with increased risk

35 e on chronic methadone should continue their maintenance dose during the perioperative period.

36 bleeding with prasugrel should focus on the maintenance dose (e.g., reduction in maintenance dose in

37 d on experimental days 2 and 6 after the MPD maintenance dose followed by 3 days of washout.

38 300-600 mg loading dose or continuation with maintenance dose followed by 75 mg per day) for 6-12 mon

39 ew protocol (1000-mg load followed by 500-mg maintenance dose for patients <70 kg, 1250-mg followed b

40 rel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months.

41 ated the full dose at day 1 and received the maintenance dose from the start at home.

42 /- 500 grains/m(3) , then randomized to four maintenance dose groups of rBet v 1-FV and one placebo g

43 The target maintenance dose had no effect on the primary outcome, b

44 Fifty-five (72%) patients reached the maintenance dose (HD) during therapy.

45 gression (SVR) to the prediction of warfarin maintenance dose in a cohort of African Americans.

46 on the maintenance dose (e.g., reduction in maintenance dose in previously reported high-risk subgro

47 as to assess the functional impact of a high maintenance dose in T2DM patients with suboptimal clopid

48 cyclosporine dosing patterns over the years, maintenance doses in 1469 living donor and 1486 cadaver

49 udesonide-formoterol in addition to the four maintenance doses in the SMART group or more than 16 act

50 300-600 mg oral loading dose plus 75 mg oral maintenance dose) in 56 patients undergoing nonurgent PC

51 Of 473 patients who received at least one CM maintenance dose (including two patients assigned to no

52 er donor graft recipients, the mean 12-month maintenance dose increased from 6.4 mg/kg per day in 198

53 y with BV given weekly x 3 doses followed by maintenance dosing (initial dose 0.6 mg/kg IV weekly).

54 this model predicts accurately the effective maintenance dose is currently being investigated.

55 Determining the optimal methadone maintenance dose is time consuming; currently, no biomar

56 For maintenance dosing, LBW seems to be a more appropriate d

57 d at the beginning and just before the first maintenance dose (MD) of 100 mug of ultra-rush VIT (day

58 ) followed by a ticagrelor 90-mg twice-daily maintenance dose (MD), aspirin-treated patients (N = 110

59 placebo loading dose (LD)/clopidogrel 75 mg maintenance dose (MD), placebo LD/prasugrel 10 mg MD, or

60 tanyl (loading dose [LD] 50 micrograms kg-1, maintenance dose [MD] 2 micrograms kg-1 min-1), or high-

61 e [n=57]), clopidogrel (600-mg load, 75-mg/d maintenance dose [n=54]), or placebo (n=12) for 6 weeks.

62 received ticagrelor (180-mg load, 90-mg BID maintenance dose [n=57]), clopidogrel (600-mg load, 75-m

63 Patients received a maintenance dose of 1.0 mg/0.02 ml of intravitreal ganci

64 y subcutaneously for one week, followed by a maintenance dose of 1.5 mg per day) or placebo.

65 Aspirin desensitization with a maintenance dose of 100 mg daily has a positive impact o

66 lled aspirin desensitization protocol with a maintenance dose of 100 mg daily.

67 TID for 2 weeks) followed by the randomized maintenance dose of 15 or 20 mg BID for 2 more weeks.

68 ered twice daily for 24 hours, followed by a maintenance dose of 200 mg twice daily for 20 days, with

69 The treatment aimed at reaching a maintenance dose of 200 ml CM (high dose = HD).

70 domly assigned again to receive a brodalumab maintenance dose of 210 mg every 2 weeks or 140 mg every

71 escalating doses from 50 mg/d to the target maintenance dose of 300 mg/d in weeks 6 to 12, combined

72 Twelve subjects then reached the maximum maintenance dose of 4000 mg peanut flour per day in a me

73 namic (PD) response to the reduced prasugrel maintenance dose of 5 mg in very elderly (VE) patients (

74 immunological response, and tolerability, a maintenance dose of 80 mug of rBet v 1-FV appears to be

75 tients undergoing cardiac surgery while on a maintenance dose of aspirin and clopidogrel (n=45), pras

76 The optimal maintenance dose of aspirin desensitization to prevent n

77 east 2 platelet function results on the same maintenance dose of clopidogrel (75 mg or 150 mg) were a

78 A 150-mg maintenance dose of clopidogrel is associated with enhan

79 stable cardiovascular disease, tripling the maintenance dose of clopidogrel to 225 mg daily in CYP2C

80 ed with clopidogrel is associated with a low maintenance dose of concomitant aspirin.

81 The mean maintenance dose of corticosteroids was slightly lower i

82 6% for each incremental increase of 1 mg/kg maintenance dose of cyclosporine (within the dose range

83 Recent evidence has shown that a single maintenance dose of heroin attenuates psychophysiologica

84 The mean (+/- SD) maintenance dose of LEF was 19.6 +/- 1.99 mg/day in year

85 me of subjects assigned to a standard or low maintenance dose of lithium.

86 rom the hospital the following day, with the maintenance dose of one whole egg to be taken daily.

87 Both the loading dose and maintenance dose of prasugrel were superior to clopidogr

88 te more than two decades of use, the optimal maintenance dose of tacrolimus for kidney transplant rec

89 linical response to the standard 75-mg daily maintenance dose of the antiplatelet drug clopidogrel.

90 We aimed to compare the effect of maintenance dose of ticagrelor versus prasugrel on coron

91 The mean (+/-SE) maintenance dose of warfarin differed significantly amon

92 (aged >/=18 years) who were taking a stable maintenance dose of warfarin were obtained at Internatio

93 ercutaneous coronary revascularization, with maintenance doses of 10 or 20 mg of xemilofiban or place

94 ted with 300 mg of rilonacept and then given maintenance doses of 100 mg/week.

95 Maintenance doses of 13-cis-retinoic acid were then admi

96 p 1), 1 loading dose of 750 mg followed by 9 maintenance doses of 150 mg (group 2), or 10 doses of 37

97 lock-randomized 1:1 to receive E-OIT at goal maintenance doses of 300 or 3000 mg/d in a double-blinde

98 mens: 1 loading dose of 750 mg followed by 9 maintenance doses of 500 mg (group 1), 1 loading dose of

99 at a dose of 540,000 IU followed by monthly maintenance doses of 90,000 IU for 5 months.

100 inistration (FDA) black box warning to avoid maintenance doses of aspirin (ASA) >100 mg/daily.

101 This study evaluated whether higher maintenance doses of buprenorphine and methadone are sup

102 Maintenance doses of clopidogrel for 4 treatment periods

103 ed seventy-eight patients were randomized to maintenance doses of either 50 mug (90 patients) or 100

104 Maintenance doses of lorazepam 0.02+/-0.01 mg/kg/hr, mid

105 he relative contributions of the loading and maintenance doses of prasugrel on events in a TRITON-TIM

106 Mean daily maintenance doses of prednisone and mycophenolate mofeti

107 Cumulative and maintenance doses of prednisone and time elapsed since t

108 Animals received the corresponding maintenance doses of the antiplatelet agents during the

109 In the groups receiving maintenance doses of ustekinumab every 8 weeks or every

110 Patients who required larger weekly maintenance doses of warfarin were less likely to have a

111 ic variants have been shown to require lower maintenance doses of warfarin, but a direct association

112 luate platelet reactivity during loading and maintenance dosing of ticagrelor versus clopidogrel, and

113 ive prasugrel (60 mg loading dose [LD]/10 mg maintenance dose once daily) or ticagrelor (180 mg LD/90

114 grel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose

115 g/kg; pertuzumab 840 mg loading dose, 420 mg maintenance doses) or docetaxel, carboplatin, and trastu

116 fined daily statin dose (the assumed average maintenance dose per day) were 0.82 (95% CI, 0.81 to 0.8

117 rcutaneous coronary intervention entered the maintenance-dose phase, a 28-day crossover comparison of

118 During the maintenance-dose phase, IPA with 20 mumol/L ADP was high

119 n; trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance doses) plus pertuzumab [same dosing as in th

120 lobulin and casein are associated with lower maintenance dose reached.

121 before OIT start were associated with lower maintenance dose reached.

122 A lower maintenance dose reduces the risk of repeated reactions,

123 fety and efficacy of adalimumab double-blind maintenance dosing regimens following open-label inducti

124 Under each maintenance dose, six experimental sample and choice ses

125 ith elinogrel up to 6 hours after daily oral maintenance dosing, these differences were not statistic

126 nance over 22 to 40 weeks, followed by daily maintenance dosing through month 28.

127 se of 9 MU and a 9-MU twice-daily fractioned maintenance dose, titrated on renal function.

128 e once daily) or ticagrelor (180 mg LD/90 mg maintenance dose twice daily) for 1 week.

129 eight) or placebo intravenously, followed by maintenance doses until delivery or 34 weeks of gestatio

130 Mean maintenance dose varied significantly among the 6 genoty

131 of higher daily buprenorphine and methadone maintenance doses vs lower doses for reducing illicit op

132 current treatment efficacy study, the target maintenance dose was randomized to either 50 mug or 100

133 Maintenance dosing was stopped completely on day 38.

134 (Prasugrel/Clopidogrel Maintenance Dose Washout Study; NCT01014624).

135 esponses (adenosine diphosphate 20 muM) post-maintenance dose were 44+/-15% for clopidogrel and 28+/-

136 After initial maintenance doses were reached, doses were adjusted down

137 le of only 1 week was applied to achieve the maintenance dose which was administered monthly during t

138 t period of time on an as-needed basis, with maintenance dosing, which provides smaller amounts of ir

139 Groups A and C received standard maintenance dosing with tacrolimus (TAC), mycophenolate

140 ng protocol (1000-mg load followed by 500-mg maintenance dose, with doses infused during the last hou

141 ved 1-day PN/WN/CSH rush OIT plus 3 weeks of maintenance dosing, with or without 3 weeks prior and 3

142 ng schedules because it allows achieving the maintenance dose within a shorter time interval.